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ABSTRACT 
Background: Sentinel lymph node biopsy (SLNB) is a widely accepted standard 
procedure for patients with clinically localized melanoma. Melanoma prevalence and 
Clark’s subtype differ between Asians and Caucasians. Here we evaluated our 
experience on SLNB for cutaneous melanoma in a Japanese population. 
Methods: SLNB was performed for patients with melanoma between July 2000 and 
June 2014. We retrospectively analyzed 102 patients regarding association of 
clinicopathological features with sentinel lymph node (SLN) status, melanoma-specific 
survival (MSS), and disease-free survival (DFS). 
Results: A positive SLN was significantly associated with primary Breslow thickness. 
Compared with 43 patients with negative SLN, 59 patients with positive SLN had 
significantly shorter MSS (5-year survival rate, 94.3% vs. 63.2%, p = 0.0002) and DFS 
(5-year survival rate, 92.7% vs. 63.4%, p = 0.0004). According to our subgroup 
analyses, nine patients with positive non-SLN had significantly shorter MSS compared 
with 32 patients with negative non-SLN (5-year survival rate, 32.4% vs. 68.5%, p = 
0.0273). The survival of 51 Japanese patients with acral lentiginous melanoma (ALM) 
was not inferior to the survival of patients with other Clark’s subtype.  
Conclusions: Breslow thickness is an important factor for both MSS and DFS, and the 
status of SLN is the most predictive prognostic factor in Japanese patients with 
clinically localized melanomas, as in case of Caucasians. Features of ALM may be 
different between Asians and Caucasians.  
Key words: sentinel lymph node biopsy, clinically localized melanoma, melanoma, 
disease-free survival, melanoma-specific survival   
INTRODUCTION 
Involvement of regional lymph nodes is the most important prognostic factor for 
survival and recurrence among individuals with cutaneous melanoma.1-4 Since the first 
report by Morton et al.1 in 1992, numerous studies have proven the prognostic value of 
sentinel lymph node biopsy (SLNB),2,5-9 and the American Joint Committee on Cancer 
(AJCC) has recommended SLNB for patients with certain types of melanoma, such as 
thick (>1 mm) or ulcerated melanomas.10 However, compared with the Western 
countries, in Asian countries, where melanoma is relatively uncommon, few studies on 
the use of SLNB11-17 have been conducted. In addition to differences in prevalence, 
Asians and Caucasians differ in terms of Clark’s subtype. Among Caucasians, 
superficial spreading melanoma (SSM) is the most common subtype and acral 
lentiginous melanoma (ALM) is the fourth common subtype.18,19 In contrast, ALM is 
the most common subtype among Asians and it has a worse prognosis for Caucasians 
compared with other Clark’s subtype.18,20,21 
The objectives of the present study were to investigate the clinical usefulness of 
SLNB and to evaluate the outcomes based on the status of SLN among Japanese 
patients with clinically localized cutaneous melanoma. 
 
METHODS 
Patients 
This was a retrospective study of 107 patients who underwent SLNB for cutaneous 
melanoma at Okayama University Hospital between July 2000 and June 2014. Patients 
with melanoma in situ (n = 5) and those with clinical or radiographic evidence of lymph 
node and visceral metastases were excluded.  
SLNB has been performed for patients with cutaneous melanoma at Okayama 
University Hospital since 1999; however, these procedures were performed by dye 
method alone, which has a poor SLN detection rate. Since 2000, the method for SLNB 
included a combination of dye, radioisotope, and gamma probe; the study period 
included procedures that used this combination.  
The clinicopathological features and outcomes of the study population were reviewed. 
Variables recorded were sex, age, location, Clark’s subtype, Breslow thickness, Tumor 
(T) stage, presence of ulceration, Clark level, number of SLNs, relapse, and outcomes. 
Written informed consent for SLNB was obtained from all patients and this study was 
approved by the Institutional Ethics Committee of Okayama University. 
 
SLNB procedure 
Preoperative lymphoscintigraphy was performed in all patients by injecting 
Tc-99m-phytate intradermally around the primary site or surgical scar of excisional 
biopsy. Dynamic and static images were obtained beginning 15 min after injection and 
continuing every 5 min until an SLN was visualized. The position of SLN was marked 
with a pen after identification using handheld gamma probe. Since 2011, a combination 
of single-photon emission computed tomography and computed tomography 
(SPECT/CT) has been used at our institution for accurate visualization of SLNs. 
The procedure was as follows: After administering general or spinal anesthesia, a 
blue dye was injected intradermally around the primary tumor or scar of a previous 
excisional biopsy and then SLNs were identified with a handheld gamma probe. Lymph 
nodes that stained blue and showed more than one-tenth radioactivity compared with 
the most active lymph node were regarded as SLNs. After excising the SLNs, 
radioactive count was measured ex vivo using the handheld gamma probe. The 
radioactive count of the lymph node basin was also measured to confirm whether there 
were any other radioactive nodes in the area. 
 
Histopathological evaluation 
Each excised SLN was fixed in formalin, bisected along the major axis, and embedded 
in paraffin. Next, 10–20 serial sections were obtained from each specimen and then 
stained with hematoxylin and eosin (HE) and processed for immunohistochemistry 
(IHC) using S-100, HMB45, tyrosinase, and MART-1 (the protein antigen). If the 
presence of tumor cells in SLNs was confirmed by HE or IHC, complete lymph node 
dissection (CLND) was recommended and performed in majority of patients. In almost 
all patients, surgery was performed the day after SLNB. We stratified patients with 
positive SLN who underwent subsequent CLND into two subgroups, depending on the 
presence of tumor cells in non-SLNs: negative non-SLN and positive non-SLN. 
 
Statistical analysis 
All statistical analyses were performed using IBM SPSS Statistics version 20.0 (SPSS 
Inc., Chicago, IL, USA). Associations between SLN positivity and other 
clinicopathological parameters were assessed using a either Chi-square test or Fisher 
exact test for categorical variables and Student’s t-test for continuous variables. 
Melanoma-specific survival (MSS) was calculated from the date of first 
histopathological examination to the date of death from melanoma or the date of last 
follow-up examination. Disease-free survival (DFS) was calculated from the date of 
first histopathological examination to the date of first disease relapse or the date of last 
follow-up examination. Kaplan–Meier method was used to evaluate MSS and DFS and 
log-rank test was used to compare survival curves. Univariate analysis was performed 
using Cox proportional hazard model to identify prognostic factors for MSS and DFS. 
Factors with a p-value of <0.10 in the univariate analysis were further analyzed by 
multivariate analysis. All statistical tests were two-sided. Significance level was 
determined at p < 0.05. 
 
RESULTS 
Patient data 
The characteristics of the 102 consecutive patients with clinically localized cutaneous 
melanomas are shown in Table 1. There were 43 male patients (42.2%) and 59 female 
patients (57.8%). Mean age at diagnosis was 62.5 years (range 21–94). In this patient 
series, Clark’s subtype of all melanomas located on the hands and feet was ALM, which 
was also the most frequent subtype (n = 51, 50%). Mean Breslow thickness was 3.36 
mm (range 0.31–13.0). T stage was pT1 in 16 patients (15.7%), pT2 in 20 patients 
(19.6%), pT3 in 37 patients (36.3%), and pT4 in 29 patients (28.4%). Ulceration was 
present in 57 patients (55.9%). Clark level was II in six patients (5.9%), III in 21 
patients (20.6%), IV in 55 patients (53.9%), and V in 20 patients (19.6%). Mean number 
of SLNs was 2.57 (range 1–7). Median follow-up duration was 54.5 months (range 6–
160). During follow-up, relapses were observed in 20 patients (19.6%): three showed 
local, satellite, or in-transit metastases; one patient showed regional lymph node 
metastasis; and 16 patients developed distant metastases as the first site of relapse. 
Twenty-four patients (23.5%) died during follow-up, 18 of them due to secondary 
melanoma. 
 
SLNB results and comparison of patients with positive and negative SLNs 
Among 102 patients with invasive cutaneous melanomas, SLN detection rate was 100%. 
Forty-three patients (42.2%) showed presence of tumor cells in SLNs; of these, 41 
(95.3%) underwent subsequent CLND, whereas the remaining two (4.7%) refused 
additional surgical intervention. None of these patients who refused surgery had 
relapses during follow-up. Of the 41 patients who underwent CLND, nine (22.0%) 
showed involvement of a non-SLN; of these positive non-SLN patients, five (55.6%) 
had relapses. During follow-up, none of the patients with negative SLN showed 
regional lymph node metastasis. Therefore, the rate of false-negative patients was 0%. 
The characteristics of patients with positive and negative SLNs are shown in Table 
2. Among the 16 pT1-stage patients, presence of tumor cells in SLNs was detected in 
five (31.2%); these 5 patients had Breslow thicknesses of 0.70, 0.70, 0.75, 0.90, and 
0.74 mm and three of them (60.0%) had no ulceration (i.e., pT1a disease). Among the 
10 patients with Breslow thickness values <0.75 mm, three (30.0%) had positive SLN.  
We observed significant differences in pathological features between patients with 
positive SLN and those with negative SLN for Breslow thickness (p = 0.0184) and T 
stage (p = 0.0188). Relapses were significantly more frequent in patients with positive 
SLN than those with negative SLN (34.9% vs. 8.5%, p = 0.0019). There were no 
significant differences between these two groups in terms of sex, age, location, Clark’s 
subtype, presence of ulceration, Clark level, and the number of SLNs. 
 
Survival analyses 
Median follow-up duration for MSS was 54.5 months (range 6–166) and that for DFS 
was 54.5 months (range 3–166). Patients with positive SLN had significantly shorter 
5-year survival rates for MSS (63.2% vs. 94.3%; p = 0.0002; Fig. 1) and DFS (63.4% vs. 
92.7%; p = 0.0004; Fig. 2) compared with patients with negative SLN. Both MSS and 
DFS were better in patients with negative SLN than those with positive SLN. 
Of the 43 patients with positive SLN, 41 (95.3%) underwent additional CLND, 
and only nine of the 41 patients (22.0%) showed involvement of a non-SLN. In the 
subgroup analysis that compared negative non-SLN (n = 32) and positive non-SLN (n = 
9), the 5-year MSS rate was significantly shorter for patients with positive non-SLN 
compared with those with negative non-SLN (32.4% vs. 68.5%; p = 0.0273; Fig. 3); the 
difference in 5-year DFS rate between these subgroups did not reach statistical 
significance (40.0% vs. 67.9%; p = 0.0765; Fig. 4). 
 
Univariate and multivariate analyses 
The factors associated with MSS and DFS are shown in Tables 3 and 4, respectively. In 
the univariate analysis for MSS, significant prognostic factors were Breslow thickness 
(p < 0.0001), presence of ulceration (p = 0.0268), number of SLNs (p = 0.0103), and 
positive SLN (p = 0.0017). These four factors and Clark level (p < 0.10) were also 
included in the subsequent multivariate analysis (Table 3), which revealed that the 
independent prognostic factors associated with MSS were Breslow thickness [hazard 
ratio (HR) 1.37, 95% confidence interval (CI) 1.14–1.65, p = 0.0007] and positive SLN 
(HR 8.88, 95% CI 2.22–35.57, p = 0.0020). In the univariate analysis for DFS, the 
significant prognostic factors were Breslow thickness (p < 0.0001), presence of 
ulceration (p = 0.017), Clark level (p = 0.0346), number of SLNs (p = 0.0318), and 
positive SLN (p = 0.0014). These five factors were included in the subsequent 
multivariate analysis (Table 4), which showed that the important prognostic factors 
associated with DFS were Breslow thickness (HR 1.28, 95% CI 1.09–1.50, p = 0.0029) 
and positive SLN (HR 5.13, 95% CI 1.77–14.91, p = 0.0026).  
 
DISCUSSION 
Involvement of regional lymph nodes is the most important prognostic factor for 
patients with cutaneous melanoma.1-4 Therefore, SLNB, which can potentially identify 
patients with occult nodal involvement, has been a standard procedure for patients with 
clinically localized melanomas. Because SLNB is accounted for in the final version of 
melanoma staging and classification10, it plays an important role in not only 
prognostication but also staging. In this study, both MSS and DFS were better in the 
patients with negative SLN than those with positive SLN (Figs. 1 and 2). 
These results suggest that the status of an SLN is a strong predictor of survival in 
Japanese patients with clinically localized melanomas. Although occult tumor cell 
involvement of regional lymph nodes exists, these metastases are too small to detect at 
this stage by imaging methods such as ultrasound, computed tomography, magnetic 
resonance imaging, and positron emission tomography. Therefore, at our institute, we 
have been performing SLNB for all patients with clinically localized melanomas, except 
patients clinically considered to have melanoma in situ, although SLNB is generally 
performed for patients with 1.0–4.0-mm-thick primary melanoma. 
According to consensus in the National Comprehensive Cancer Network 
Guidelines,22 SLNB should be discussed and offered to patients with primary 
melanomas >1.0 mm thick. In general, SLNB is not recommended for melanomas that 
are ≤0.75 mm in Breslow thickness. For melanomas that are 0.76–1.0 mm thick, SLNB 
should be discussed and considered, although the yield is low and clinical significance 
is modest for a positive SLN. 
Han et al.23 observed that among 1,250 patients with melanomas <1.0 mm in 
Breslow thickness, 65 (5.2%) had positive SLN; in this report, SLNB can be avoided in 
patients with melanomas <0.75 mm in Breslow thickness and was recommended when 
the primary tumor is ≥0.75 mm in Breslow thickness, particularly if with ulceration. For 
melanomas >4.0 mm in Breslow thickness, it is generally accepted that SLNB is not 
always considered because of high risk for distant metastasis. 
The status of SLN was shown to be an important prognostic factor in pT4 
patients, as well as in patients with melanomas between 1.0 and 4.0 mm in Breslow 
thickness.9,24 In this study, five of 16 (31.2%) patients with Breslow thickness values 
<1.0 mm had positive SLN; three of 10 (30.0%) patients with Breslow thickness values 
< 0.75 mm had positive SLN. These results suggest a higher rate of SLN positivity in 
this cohort of Asian patients with Breslow thickness values <1.0 mm compared with 
Caucasians. Although the number of patients in this study was small, the adaptive 
criteria for SLNB in Japanese populations, which differ from those for Caucasians, may 
be established by future large-scale studies. 
The incidence of melanoma in Asian countries is lower than that in Western 
countries. There are fewer studies on SLNB from Asian countries11-17 compared with 
Western countries. The studies performed in Asian countries have revealed rates of SLN 
positivity ranging 15.5%–41.8%.11-17 The rate of SLN positivity in this study was 42.2%, 
which is relatively high compared with previously obtained values. This result may be 
attributable to the exclusion of patients with melanoma in situ who underwent SLNB; if 
these patients (n = 5) were included in our analyses, SLN positivity rate would have 
decreased to 40.2%, which is consistent with previous studies, but is still higher than the 
rates shown in Caucasian studies.25 The result may be associated with increased 
Breslow thickness values, which correlates with SLN positivity, observed in the present 
study population compared with those of patients in most Caucasian studies.22 
In a US-based study, Bradford et al.18 demonstrated that ALM had greater Breslow 
thickness values than other Clark’s subtype. Among patients with ALM in Western 
countries, majority of whom are Caucasians, the rates of SLN positivity ranged 24%–
40%.21,26,27 Furthermore, prognosis of ALM in Caucasians was considered worse 
compared with other subtypes.18,20,21 In Asian countries, where ALM is the most 
common subtype, ALM is not always considered to have a worse prognosis compared 
with others. Among patients with clinically localized melanomas, survival of patients 
with ALM who underwent SLNB was not inferior compared with that of patients with 
others (Tables 3 and 4). Uhara et al.13 reported that the prognosis in Japanese patients 
with melanoma was similar to that in Caucasians, although majority of their patients 
had ALM. In addition, studies in Taiwan14, 28 found that ALM is an independent 
prognostic factor for better overall survival in multivariate analysis. These results 
suggest that features of ALM, including prognosis, are different between Asians and 
Caucasians. 
Our present findings revealed that Breslow thickness was an important factor for 
both MSS and DFS and that SLN positivity was the most predictive prognostic factor in 
patients with clinically localized melanomas. Despite the small number of patients, 
these results are consistent with those of previous studies on Caucasians.2-4,20,29 In 
general, patients with negative SLN are spared of further surgery and patients with 
positive SLN undergo additional CLND of the regional basin. In the present study, only 
9 of 41 (22.0%) patients who underwent additional CLND showed involvement of a 
non-SLN. That is, the remaining 32 (78.0%) patients did not have involvement of a 
non-SLN and additional CLND could be avoided. 
According to a meta-analysis in 2013, the rate of non-SLN positivity ranged 7.8–
38.3%.30 Therefore, although additional CLND is recommended for patients with 
positive SLN, the therapeutic effect remains unclear. The Multicenter Selective 
Lymphadenectomy Trial-I (MSLT-I)2 was initiated in 1994 to assess therapeutic benefit 
of SLNB and subsequent CLND for patients with a positive SLN. Patients with 
melanomas of at least 1-mm Breslow thickness or Clark level IV were randomized 
either to SLNB with subsequent CLND, if SLN metastasis was found, or to observation 
with CLND when regional lymph node metastasis was revealed later. The final report of 
the MSLT-I4 showed that in patients with intermediate-thickness melanomas, defined as 
1.20–3.50 mm, and those with thick melanomas, defined as >3.5 mm, performing 
SLNB significantly improved 10-year DFS rates compared with nodal observation. 
However, the performance of SLNB showed no improvement in 10-year MSS rates for 
both intermediate-thickness and thick melanomas. 
In a subgroup analysis of MSLT-I of patients with positive SLN from 
intermediate-thickness melanomas, the 10-year MSS rates significantly improved for 
patients who had undergone subsequent CLND compared with those with delayed 
CLND (62.1% vs. 41.5%, respectively, p = 0.006).4 Other studies demonstrated that in 
patients with positive SLN, there was no significant difference in MSS between those 
who underwent immediate CLND and those who underwent nodal observation only.31-33 
In addition, among patients with positive SLN, systemic recurrence occurred in 8% of 
nodal observation patients compared with 27% of those who underwent immediate 
CLND (p < 0.001).31 Complications occurred more frequently in patients subjected to 
CLND after SLNB than those who had SLNB alone.34,35 Therefore, although SLNB 
plays an important role in prognostication of patients with clinically localized 
melanomas, the therapeutic effect of additional CLND after SLNB has not been 
demonstrated. These results suggest that patients who have low risk for non-SLN 
positivity could be spared from CLND, even if they are SLN positive. 
It was demonstrated that involvement of a non-SLN was the most important 
predictor of poor survival in patients with positive SLN who proceeded to have 
CLND.36, 37 In the present study, the 5-year MSS was significantly shorter for patients 
with positive non-SLN compared with patients with negative non-SLN. Therefore, 
several attempts have been made to predict involvement of non-SLN based on 
clinicopathological factors of patients who underwent CLND after SLNB. According to 
the 2013 meta-analysis, factors that were found to be significantly associated with 
non-SLN positivity were presence of ulceration, satellitosis, neurotropism, >1 positive 
SLN, angiolymphatic invasion, extensive location, macrometastases >2 mm, extranodal 
extension, and capsular involvement. Based on the results of 450 Japanese patients who 
underwent SLNB, Namikawa et al.12 demonstrated that a <1.0-mm maximum diameter 
of melanoma with SLN was a predictor of the absence of non-SLN positivity. It may be 
possible to omit CLND for patients at low risk for non-SLN positivity. However, there 
is no precise evidence with regard to omitting CLND for patients with positive SLN. 
Therefore, at our institute majority of such patients undergo CLND after SLNB. 
A current prospective study the Multicenter Selective Lymphadenectomy Trial II 
(MSLT-II)38 is comparing CLND with close follow-up by ultrasound, in patients with 
positive SLN. The results of these trials may provide valuable information regarding 
patients who could be spared of CLND.  
Systemic therapy had not been shown to improve survival in patients with 
metastatic melanomas until 2011. Dacarbazine alone had been the international standard 
cytotoxic chemotherapy, despite its low response rate. Currently, there are some novel 
agents that improve survival in patients with inoperable regional and visceral 
metastases: MAP kinase pathway inhibitors, such as vemurafenib, dabrafenib and 
trametinib, and immunotherapy with ipilimumab and nivolumab. In the near future, the 
value of these new agents for adjuvant therapy may be demonstrated in patients with 
earlier melanomas (i.e., operable regional metastases). Then, SLNB will play important 
roles in not only prognostication but also selection of patients who will benefit from 
these agents. When adequate systemic therapy becomes available, the importance of 
SLNB is likely to increase. 
In conclusion, we observed that Breslow thickness is an important factor for both MSS 
and DFS, and the status of SLN is the most predictive prognostic factor in Japanese 
patients with clinically localized melanomas who undergo SLNB. These results are 
consistent with those in Caucasians, although the features of ALM are different between 
Asians and Caucasians. However, the benefit of additional CLND for patients with 
positive SLN remains unclear. Depending on the result of the MSLT-II trial, additional 
CLND could be spared in some patients, even if SLNs are positive.  
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FIGURE LEGENDS  
Figure 1. Kaplan–Meier curve for melanoma-specific survival (MSS) according to 
sentinel lymph node status (positive, n = 43; negative, n = 59).  
 
Figure 2. Kaplan–Meier curve for disease-free survival according to sentinel lymph 
node status (positive, n = 43; negative, n = 59).  
 
Figure 3. Kaplan–Meier curve for melanoma-specific survival according to 
non-sentinel lymph node status (positive non-SLN, n = 9; negative non-SLN, n = 32). 
 
Figure 4. Kaplan–Meier curve for disease-free survival according to non-sentinel 
lymph node status (positive non-SLN, n = 9; negative non-SLN, n = 32). 
 
 
  
TABLES 
Table 1. Clinicopathological features of 102 patients with invasive cutaneous melanoma 
who underwent sentinel lymph node biopsy  
 
SSM, superficial spreading melanoma; NM, nodular melanoma; ALM, acral lentiginous 
melanoma. 
  
Parameters No. of patients (%)
Gender
 Male 43 (42.2%)
 Female 59 (57.8%)
Mean age (range) 62.5 (21-94)
Primary site
 Head and neck 14 (13.7%)
 Trunk and extremities 37 (36.3%)
 Hand and foot 51 (50.0%)
Histopathological subtype
 SSM 38 (37.2%)
 NM 6 (5.9%)
 ALM 51 (50.0%)
 Other 7 (6.9%)
Mean Breslow th ickness (range) 3.36 (0.31-13.0)
T stage
 T1 16 (15.7%)
 T2 20 (19.6%)
 T3 37 (36.3%)
 T4 29 (28.4%)
Ulceration
 Present 57 (55.9%)
 Absent 45 (44.1%)
Clark level
 Ⅱ 6 (5.9%)
 Ⅲ 21 (20.6%)
 Ⅳ 55 (53.9%)
 Ⅴ 20 (19.6%)
Mean number of SLNs (range) 2.57 (1-7)
Relapse
 Yes 20 (19.6%)
 No 82 (80.4%)
Site of f irst re lapse
 Local/Satellite/in-transit metastases 3 (15.0%)
 Regional lymph nodemetastases 1 (5.0%)
 Distant metastases 16 (80.0%)
Death
 Yes 24 (23.5%)
 No 78 (76.5%)
Cause of death
 due to melanoama 18 (75.0%)
 other cause 6 (25.0%)
Table 2. Clinicopathological features associated with status of sentinel lymph nodes in 
patients with cutaneous melanoma (n = 102) 
 
 
SSM, superficial spreading melanoma; NM, nodular melanoma; ALM, acral lentiginous 
melanoma; SLN, sentinel lymph node; NA, not applicable. 
  
patients with a positive SLN (n = 43, 42.2%) patients with a negative SLN (n = 59, 57.8%) 
Parameters No. of patients (%) No. of patients (%) p value
Gender 0.8394
 Male 19(44.2%) 24(40.7%)
 Female 24(55.8%) 35(59.3%)
Mean age (range) 64.5(30-91) 61.0(21-94) 0.2965
Primary site 0.7918
 Head and neck 6(13.9%) 8(13.6%)
 Trunk and extremities 14(32.6%) 23(39.0%)
 Hand and foot 23(53.5%) 28(47.4%)
Histopathological subtype 0.4524
 SSM 14(32.6%) 24(40.7%)
 NM 4(9.3%) 2(3.4%)
 ALM 23(53.5%) 28(47.4%)
 Other 2(4.6%) 5(8.5%)
Mean Breslow th ickness (range) 4.09(0.70-13.0) 2.83(0.31-13.0) 0.0184
T stage 0.0188
 T1 5(11.6%) 11(18.6%)
 T2 5(11.6%) 15(25.4%)
 T3 14(32.6%) 23(39.0%)
 T4 19(44.2%) 10(17.0%)
Ulceration 0.0686
 Present 29(67.4%) 28(47.5%)
 Absent 14(32.6%) 31(52.5%)
Clark level 0.1881
 Ⅱ 1(2.3%) 5(8.5%)
 Ⅲ 6(14.0%) 15(25.4%)
 Ⅳ 25(58.1%) 30(50.8%)
 Ⅴ 11(25.6%) 9(15.3%)
Mean number of SLNs(range) 2.86(1-7) 2.36(1-7) 0.1152
Relapse 0.0019
 Yes 15(34.9%) 5(8.5%)
 No 28(65.1%) 54(91.5%)
Site of f irst re lapse 0.8007
 Local/Satellite/in-transit metastases 2(13.3%) 1(20.0%)
 Regional lymph node metastases 1(6.7%) 0(0.0%)
 Distant metastases 12(80.0%) 4(80.0%)
Patients with a positive non-SLN 9 (22.0%) NA
Table 3. Univariate and multivariate analyses of factors associated with 
melanoma-specific survival in patients with cutaneous melanoma who underwent 
sentinel lymph node biopsy (n = 102) 
 
 
HR, Hazard ratio; CI, Confidence interval; ALM, acral lentiginous melanoma; SLN, 
sentinel lymph node. 
  
Univariate Multivariate
Factor HR (95% CI) p value HR (95% CI) p value
Age (years) 1.02 (0.99-1.05) 0.2911
Gender (male vs female) 1.52 (0.59-3.94) 0.3893
Primary site (hand and foot vs the others) 0.92 (0.35-2.39) 0.8641
Histopathological subtype (ALM vs the others) 0.92 (0.35-2.39) 0.8641
Breslow thickness (㎜) 1.32 (1.17-1.49) < 0.0001 1.37 (1.14-1.65) 0.0007
Ulceration (present vs absent) 4.09 (1.18-14.25) 0.0268 1.13 (0.28-4.59) 0.8556
Clark level (Ⅳ or Ⅴ vs Ⅱ or Ⅲ) 6.98 (0.92-52.66) 0.0597 2.27 (0.25-20.47) 0.4636
Number of SLNs 1.38 (1.08-1.75) 0.0103 1.21 (0.92-1.60) 0.1659
Status of SLNs (positive vs negative) 7.37 (2.12-25.65) 0.0017 8.88 (2.22-35.57) 0.0020
Table 4 Univariate and multivariate analyses of factors associated with disease-free 
survival in patients with cutaneous melanoma who underwent sentinel lymph node 
biopsy (n = 102) 
 
 
HR, Hazard ratio; CI, Confidence interval; ALM, acral lentiginous melanoma; SLN, 
sentinel lymph node. 
  
Univariate Multivariate
Factor HR (95% CI) p value HR (95% CI) p value
Age (years) 1.03 (0.99-1.06) 0.1106
Gender (male vs female) 1.05 (0.44-2.48) 0.9185
Primary site (hand and foot vs the others) 0.60 (0.25-1.46) 0.2627
Histopathological subtype (ALM vs the others) 0.60 (0.25-1.46) 0.2627
Breslow thickness (㎜) 1.29 (1.15-1.44) < 0.0001 1.28 (1.09-1.50) 0.0029
Ulceration (present vs absent) 3.77 (1.27-11.20) 0.017 1.31 (0.40-4.25) 0.6573
Clark level (Ⅳ or Ⅴ vs Ⅱ or Ⅲ) 8.73 (1.17-65.10) 0.0346 3.33 (0.40-27.75) 0.2657
Number of SLNs 1.29 (1.02-1.62) 0.0318 1.14 (0.88-1.47) 0.3169
Status of SLNs (positive vs negative) 5.18 (1.89-14.18) 0.0014 5.13 (1.77-14.91) 0.0026
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